Predict your next investment

Avita Medical company logo
HEALTHCARE | Biotechnology
avitamedical.com

See what CB Insights has to offer

Founded Year

2008

Stage

Other Investors | Alive

About Avita Medical

AVITA Medical is a global regenerative medicine company that provides a novel approach to skin regeneration. The company's products provide treatment solutions derived from the regenerative properties of a patient’s own skin. The company is based in Valencia, California.

Avita Medical Headquarter Location

28159 Avenue Stanford, Suite 220

Valencia, California, 91355,

United States

Latest Avita Medical News

AVITA Medical : Corporate Deck January 2022

Jan 11, 2022

01/11/2022 | 01:48pm EST Message : Legal Disclaimers Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVID-19 pandemic; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning AVITA Medical as well as the aforementioned risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and our most recent Annual Report on Form 10-Kfor the year ended June 30, 2021. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation. AVITA Medical's products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events. In the United States, RECELL® is approved for use in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use only). 2 Soft Tissue Pivotal Trial: Enrollment Completed Transitional Pass-Through Payment Application Approved by CMS for Reimbursement in Outpatients EB: Initial Proof of Concept for Delivery of Genetically Modified Skin Cells in Suspension Telomerase/Rejuvenation: Initial Proof of Concept on Delivery of Reverse-Aged Skin Cells Quarter Ending December '21, Total Revenue Growth of +35% vs Same Quarter Prior Year FDA Approval of Pediatric Label Expansion New Ease of Use RECELL Device under FDA Review Quarters referenced in calendar year. As of January 1, 2022 Avita Medical will report on a calendar year basis. Projected Key Milestones

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Avita Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Avita Medical is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

8,184 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

D

Diabetes

1,750 items

Avita Medical Patents

Avita Medical has filed 3 patents.

The 3 most popular patent topics include:

  • Cell biology
  • Biotechnology
  • Plastic surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/11/2020

9/21/2021

Transcription factors, Cell biology, Clusters of differentiation, Traumatology, Growth factors

Grant

Application Date

2/11/2020

Grant Date

9/21/2021

Title

Related Topics

Transcription factors, Cell biology, Clusters of differentiation, Traumatology, Growth factors

Status

Grant

Avita Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Avita Medical Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.